Oncotarget: Replication-stress sensitivity in breast cancer cells
(Impact Journals LLC) Taken together these Oncotarget findings show that the CTD and OD domains of mtp53 R273H play critical roles in mutant p53 GOF that pertain to processes associated with DNA replication. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 26, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas
(Impact Journals LLC) This Oncotarget study confirms the upregulation of TERT in primary glioblastomas while all GABP proteins rise with the malignancy of the gliomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 26, 2021 Category: Cancer & Oncology Source Type: news

Mount Sinai researchers develop novel therapy that could be effective in many cancers
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Chemotherapy can induce mutations that lead to pediatric leukemia relapse
(St. Jude Children's Research Hospital) A collaboration led by St. Jude Children's Research Hospital, Shanghai Children's Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Research identifies potential role of 'junk DNA' sequence in aging, cancer
(Washington State University) Researchers at Washington State University have recently identified a DNA region known as VNTR2-1 that appears to drive the activity of the telomerase gene, which has been shown to prevent aging in certain types of cells. Knowing how the telomerase gene is regulated and activated and why it is only active in certain cell types could someday be the key to understanding how humans age and how to stop the spread of cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Novel imaging agent identifies biomarker for iron-targeted cancer therapies
(Society of Nuclear Medicine and Molecular Imaging) A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients. The radiotracer, 18F-TRX, can be used to measure iron concentration in tumors, which can help predict whether a not the cancer will respond to treatment. This research was published in the July issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma
(Medical University of South Carolina) MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

American Society for Colposcopy and Cervical Pathology discusses updated American Cancer Society guidelines on cervical cancer screening
(Wolters Kluwer Health) Last year, the American Cancer Society (ACS) issued an updated set of guidelines for cervical cancer screening - emphasizing the shift toward screening with primary human papillomavirus (HPV) testing. While the ACS recommendation accounts for a transition period to implement primary HPV screening, additional factors should be considered to operationalize these guidelines, according to a special white paper in the July issue of the Journal of Lower Genital Tract Disease (JLGTD), official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

New organ-on-a-chip finds crucial interaction between blood, ovarian cancer tumors
(Texas A&M University) Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Fgr and Numb in retinoic differentiation and G0 arrest of non-APL AML cells
(Impact Journals LLC) In sum the Oncotarget data support a paradigm where signaling molecules bound to a Numb scaffold in a signalsome are activated by RA-induced Fgr expression (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

Study on chromosomal rearrangements in yeast reveals potential avenue for cancer therapy
(Osaka University) Researchers from Osaka University have found that the attachment of a ubiquitin molecule to a protein called PCNA at the lysine 107 position causes gross chromosomal rearrangements. This lysine is located where two PCNA molecules interact, and the ubiquitin attachment to it may change the ring structure they form. The ubiquitin attachment occurs through the action of Rad8 (a ubiquitin ligase) and Mms2-Ubc4 (a ubiquitin conjugating enzyme). This implies that inhibiting the human equivalent of this ubiquitination could prevent cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Geneticists reveal how mutation causes childhood cancer; use drug to reverse its effects
(Trinity College Dublin) Geneticists from Trinity College Dublin have discovered how a specific genetic mutation (H3K27M) causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and - in lab studies working with model cell types - successfully reverse its effects to slow cancer cell growth with a targeted drug. Their landmark work - just published in leading international journal, Nature Genetics - translates crucial new understanding of the genetics of DMG progression into a highly promising, targeted therapeutic approach and offers significant hope of improved treatments in the future. (S...
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Studies find combination chemotherapy beneficial and cost-effective in sub-Saharan Africa
(UNC Lineberger Comprehensive Cancer Center) Researchers at the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger researchers and colleagues report a study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy in a manner that is similar to patients without that mutation. This discovery runs counter to previous research that suggested FGFR3-mutated bladder cancers should not be treated with immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic research suggests women over 65 be offered hereditary cancer genetic testing
(Mayo Clinic) A new study by Fergus Couch, Ph.D., of Mayo Clinic Cancer Center, along with collaborators from the CARRIERS consortium, suggests that most women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing. The study was published Thursday, July 22, in the Journal of Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news